A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
- 1 September 2001
- Vol. 92 (5) , 1265-1271
- https://doi.org/10.1002/1097-0142(20010901)92:5<1265::aid-cncr1447>3.0.co;2-5
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced CancerJournal of Clinical Oncology, 1999
- Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)Journal of Clinical Oncology, 1999
- A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseGastroenterology, 1998
- Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutationMolecular Carcinogenesis, 1997
- Activation of the K-ras oncogene in colorectal neoplasms is Associated with decreased apoptosisCancer, 1997
- Antiapoptotic effect of ras in the apoptosis induced by serum deprivation and exposure to actinomycin DNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1997
- Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human FibroblastsPublished by Elsevier ,1996
- Development of Antisense Therapeutics: Implications for Cancer Gene TherapyAnnals of the New York Academy of Sciences, 1994
- Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the MonkeyAntisense Research and Development, 1994
- Antisense technologyCurrent Opinion in Biotechnology, 1991